STEAP 家族成员在乳腺癌中的肿瘤抑制作用和预后价值。

The Tumor Suppressive Roles and Prognostic Values of STEAP Family Members in Breast Cancer.

机构信息

Department of General Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, China.

Changjiang Scholar's Laboratory/Guangdong Provincial Key Laboratory for Diagnosis and Treatment of Breast Cancer, Shantou University Medical College, Shantou 515041, China.

出版信息

Biomed Res Int. 2020 Aug 3;2020:9578484. doi: 10.1155/2020/9578484. eCollection 2020.

OBJECTIVE

To investigate the expression patterns and prognostic values of STEAP family members in the occurrence and development of breast cancer.

MATERIALS AND METHODS

The Human Protein Atlas was used to analyze the expression level of STEAPs in human normal tissues and malignant tumors. ONCOMINE datasets were analyzed for the comparison of the STEAPs levels between malignant cancers and corresponding normal tissues. Kaplan-Meier plotter was used to analyze the prognostic value of STEAPs in breast cancer patients.

RESULTS

STEAPs were widely distributed in human normal tissues with diverse levels. Normally, it is predicted that STEAP1 and STEAP2 were involved in the mineral absorption process, while STEAP3 participated in the TP53 signaling pathway and iron apoptosis. The results from ONCOMINE showed downregulation of STEAP1, STEAP2, and STEAP4 in breast cancers. Survival analysis revealed that breast cancer patients with high levels of STEAP1, STEAP2, and STEAP4 had a good prognosis, while those with low expression had high overall mortality.

CONCLUSION

STEAP1, STEAP2, and STEAP4 are predicted to be the potential prognostic biomarkers for breast cancer patients, providing novel therapeutic strategies for them.

目的

研究 STEAP 家族成员在乳腺癌发生发展中的表达模式和预后价值。

材料与方法

利用人类蛋白质图谱分析 STEAPs 在人正常组织和恶性肿瘤中的表达水平。通过 ONCOMINE 数据集分析 STEAPs 在恶性肿瘤与其相应正常组织之间的水平比较。利用 Kaplan-Meier plotter 分析 STEAPs 在乳腺癌患者中的预后价值。

结果

STEAPs 在人正常组织中广泛分布，其水平具有多样性。正常情况下，预测 STEAP1 和 STEAP2 参与矿物质吸收过程，而 STEAP3 参与 TP53 信号通路和铁凋亡。ONCOMINE 的结果显示，乳腺癌中 STEAP1、STEAP2 和 STEAP4 下调。生存分析表明，STEAP1、STEAP2 和 STEAP4 高表达的乳腺癌患者预后良好，而低表达的患者总死亡率较高。